Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Co.'s main clinical programs are ARRY-520 Kinesin spindle protein inhibitor for multiple myeloma, ARRY-614 p38/Tie2 dual inhibitor for myelodysplastic syndromes, ARRY-797 p38 inhibitor for pain and ARRY-502 CRTh2 antagonist for asthma. Also, pharmaceutical and biotechnology companies partner with Co. to discover and develop drug candidates for a range of therapeutic areas. Co. also has internal drug discovery programs such as inhibitors targeting Trk receptors for the treatment of pain.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.
